손발톱진균증의 전신 항진균제

키워드

참고문헌 (25)

1. Schieke SM, "Fitzpatrick's dermatology in general medicine", pp.2277~2328 (2012), McGraw-Hill
2. 황성민, "한국인의 손발톱진균증 환자의 역학적 조사: 다기관 연구", 대한의진균학회지, 16(2), pp.35~43 (2011), 대한의진균학회[DOI]
3. 이원주, "Increasing Prevalence of Trichophyton rubrum Identified through an Analysis of 115,846 Cases over the Last 37 Years", Journal of Korean Medical Science, 30(5), pp.639~643 (2015), 대한의학회
4. Elewski BE, "Onychomycosis. Treatment, quality of life, and economic issues", Am J Clin Dermatol, 1, pp.19~26 (2000)
5. Ameen M, "British association of dermatologists'guidelines for the management of onychomycosis 2014", Brit J Dermatol, 171, pp.937~958 (2014)
6. Thomas J, "Toenail onychomycosis : an important global disease burden", J Clin Pharm Ther, 35, pp.497~519 (2010)
7. Lecha M, "Treatment options-development of consensus guidelines", J Eur Acad Dermatol Venereol, 19, pp.25~33 (2005)
8. Iorizzo M, "Today's treatments options for onychomycosis", J Dtsch Dermatol Ges, 8, pp.875~879 (2010)
9. Hay RJ, "Onychomycosis : a proposed revision of the clinical classification", J Am Acad Dermatol, 65, pp.1219~1227 (2011)
10. Rosen T, "Antifungal drugs for onychomycosis:efficacy, safety, and mechanisms of action", Semin Cutan Med Surg, 35, pp.S51~S55 (2016)
11. Gupta AK, "The use of oral antifungal agents to treat onychomycosis", Dermatol Clin, 21, pp.469~479 (2003)
12. Gupta AK, "A risk-benefit assessment of the newer oral antifungal agents used to treat onychomycosis", Drug Saf, 22, pp.33~52 (2000)
13. Van Duyn Graham L, "Recent updates in oral terbinafine: its use in onychomycosis and tinea capitis in the US", Mycoses, 54, pp.e679~e685 (2011)
14. Bueno JG, "In vitro activity of fluconazole, itraconazole, voriconazole and terbinafine against fungi causing onychomycosis", Clin Exp Dermatol, 35, pp.658~663 (2010)
15. Gupta AK, "Therapy for the treatment of onychomycosis", Clin Dermatol, 31, pp.544~554 (2013)
16. "Novartis Pharmaceuticals Corporation", 2016
17. Yin Z, "A meta-analysis comparing long-term recurrences of toenail onychomycosis after successful treatment with terbinafine versus itraconazole", J Dermatolog Treat, 23, pp.449~452 (2012)
18. Gupta AK, "In vitro activities of posaconazole, ravoconazole, terbinafine, itraconazole and fluconazole against dermatophyte, yeast and nondermatophyte species", Med Mycol, 43, pp.179~185 (2005)
19. Sobue S, "Intracutaneous distributions of fluconazole, itraconazole, and griseofulvin in guinea pigs and binding to human stratum corneum", Antimicrob Agents Chemother, 48, pp.216~223 (2004)
20. Debruyne D, "Pharmacokinetics of antifungal agents in onychomycoses", Clin Pharmacokinet, 40, pp.441~472 (2001)
21. "Janssen Pharmaceuticals, Inc", 2015
22. Gupta A, "Update on the safety of itraconazole pulse therapy in onychomycosis and dermatomycoses", Eur J Dermatol, 11, pp.6~10 (2001)
23. "Roerig, Division of Pfizer Inc", 2014
24. Gupta AK, "Evidencebased optimal fluconazole dosing regimen for onychomycosis treatment", J Dermatolog Treat, 24, pp.75~80 (2013)
25. Scher RK, "Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the toenail", J Am Acad Dermatol, 38, pp.S77~S86 (1998)

관련 논문AI추천